Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Yang, Hua; Tao, Yue; Zhang, Mengli; Ma, Pengcheng; Li, Lingjun; Diao, Qingchun
• Is Part Of: Anti-cancer drugs. Volume 30:Issue 1(2019)
• Publication Date: 2019-01
• Subjects: apoptosis -- 9-cis-retinoic acid -- cutaneous T-cell lymphoma -- JAK/STAT pathway -- proliferation -- RAR/RXR pathway; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000692
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : The vitamin A derivative 9-cis-retinoic acid (9-cis-RA) has been used for the treatment and prevention of cutaneous T-cell lymphoma (CTCL). However, the precise mechanism by which 9-cis-RA treatment ameliorates CTCL remains elusive. Our research shows that 9-cis-RA inhibits proliferation and induces apoptosis in CTCL cells in a dose-dependent and time-dependent manner. 9-Cis-RA also induced G0/G1 cell cycle arrest by downregulation of cyclin D1 . We confirmed that 9-cis-RA significantly decreased phosphorylation of JAK1, STAT3, and STAT5 and downregulated Bcl-xL and cyclin D1, indicating that 9-cis-RA inhibited the activation of JAK/STAT signaling. Meanwhile, 9-cis-RA also activated classical RA-mediated transcription by retinoic acid receptors ( RAR ) and/or retinoid X receptors ( RXR ) in a CTCL cell line. Thus, 9-cis-RA may be effective for chemotherapy and may prevent human CTCL by inhibiting proliferation and inducing apoptosis by inhibition of the JAK/STAT pathway and activation of the RAR/RXR pathway.